These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480 [TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334 [TBL] [Abstract][Full Text] [Related]
4. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M; Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920 [TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts. Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659 [TBL] [Abstract][Full Text] [Related]
6. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW; Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327 [TBL] [Abstract][Full Text] [Related]
7. Splicing Factor Mutations in Cancer. Bejar R Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388 [TBL] [Abstract][Full Text] [Related]
8. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis. Wang X; Song X; Yan X Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956 [TBL] [Abstract][Full Text] [Related]
9. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Hahn CN; Venugopal P; Scott HS; Hiwase DK Immunol Rev; 2015 Jan; 263(1):257-78. PubMed ID: 25510282 [TBL] [Abstract][Full Text] [Related]
10. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia. Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291 [TBL] [Abstract][Full Text] [Related]
11. It dices, it splices! Klimek VM Blood; 2011 Dec; 118(24):6237-8. PubMed ID: 22161850 [No Abstract] [Full Text] [Related]
13. Improving the outlook for myelodysplastic syndrome. Brower V J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627 [No Abstract] [Full Text] [Related]
14. The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. Chen L; Chen JY; Huang YJ; Gu Y; Qiu J; Qian H; Shao C; Zhang X; Hu J; Li H; He S; Zhou Y; Abdel-Wahab O; Zhang DE; Fu XD Mol Cell; 2018 Feb; 69(3):412-425.e6. PubMed ID: 29395063 [TBL] [Abstract][Full Text] [Related]
15. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Taskesen E; Havermans M; van Lom K; Sanders MA; van Norden Y; Bindels E; Hoogenboezem R; Reinders MJ; Figueroa ME; Valk PJ; Löwenberg B; Melnick A; Delwel R Blood; 2014 May; 123(21):3327-35. PubMed ID: 24668493 [TBL] [Abstract][Full Text] [Related]
16. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386 [TBL] [Abstract][Full Text] [Related]
17. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Damm F; Thol F; Kosmider O; Kade S; Löffeld P; Dreyfus F; Stamatoullas-Bastard A; Tanguy-Schmidt A; Beyne-Rauzy O; de Botton S; Guerci-Bresler A; Göhring G; Schlegelberger B; Ganser A; Bernard OA; Fontenay M; Heuser M Leukemia; 2012 May; 26(5):1137-40. PubMed ID: 22064355 [No Abstract] [Full Text] [Related]
18. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Pollyea DA; Harris C; Rabe JL; Hedin BR; De Arras L; Katz S; Wheeler E; Bejar R; Walter MJ; Jordan CT; Pietras EM; Alper S Haematologica; 2019 Sep; 104(9):e388-e392. PubMed ID: 30846499 [No Abstract] [Full Text] [Related]
19. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599 [TBL] [Abstract][Full Text] [Related]
20. [Gene mutation and myelodysplastic syndromes with ring sideroblast excess]. Meng FK; Huang LF; Zhou JF; Sun HY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1088-90. PubMed ID: 23998618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]